MDS+AML MATTER Patient Evaluation and Management Simulator

To address the many challenges faced by members of the interdisciplinary care team involved in the diagnosis and treatment of patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML), the American Society of Hematology (ASH), American Society for Clinical Pathology (ASCP), National Marrow Donor Program (NMDP), Oncology Nursing Society (ONS), and The France Foundation have partnered to create MDS+AML MATTER, a free education program that includes opportunities for both live and online learning.

The goals of the program are to provide guidance to the interdisciplinary MDS/AML care team on:

  • The optimal diagnosis and classification of both MDS and AML
  • Risk stratification and individualized treatment selection
  • Assessment of treatment responses
  • Monitoring for and mitigation of adverse events, and
  • Patient education regarding prognosis and treatment choices

These activities are supported by an independent medical education grant from Celgene.


MDS+AML MATTER Simulated Cases


CME
MOC
These two simulated, case-based activities allow health care professionals to virtually manage patients with MDS or AML. Each activity requires the participant to work through the case by obtaining a patient history, considering differential diagnoses, ordering and interpreting laboratory tests, and more. This virtual experience will help the clinician transfer the learned behavior into his/her practice to improve patient care.

In continuing to utilize the services provided to you, you are agreeing to leave the ASH maintained site and you understand and acknowledge that a third party may require access to your personal information to continue your use of a third-party site. You should review the privacy policy and terms of use for the third-party site for which you are being redirected for more specific information about your choices regarding the collection and use of your personal information. (Syandus AliveSim Privacy Policy)

Continue

Simulation Instructions

  • Launch the simulation on a PC, Mac, tablet, or smart phone.
  • Complete the pretest and launch the first simulation scenario. Interact appropriately to satisfy each objective to unlock the next objective.
  • The simulation will track your progress until all scenario objectives and assessment components are complete. You can exit the simulation at any time, and your progress will be saved so that you can return to finish later.
  • You must successfully complete both scenarios, to qualify for 1.00 CME/CNE credit.

Learning Objectives

  • Appropriately interpret MDS and AML testing on the basis of available evidence/guidance
  • Identify cytogenetic and molecular tests that must be performed when diagnosing MDS or AML
  • Incorporate important aspects of bone marrow specimen acquisition, preparation, and conveyance that impact the accuracy of the pathologist’s interpretation
  • Effectively use tools for classification and risk stratification, based on morphological, clinical, and genetic criteria
  • Recognize scenarios in which older patients and/or those with comorbidities may still be eligible for interventions previously considered too risky

Target Audience


The target audience for this program includes the entire interdisciplinary cancer care team involved in the diagnosis and management of patients with MDS and AML, including:
  • Hematologists
  • Oncologists
  • Hematopathologists
  • Pathologists
  • Physician assistants
  • Advanced practice nurses
  • Nurses
  • Hematopoietic cell transplantation clinicians
  • Other health care professionals

Faculty

Robert Paul Hasserjian, MD
Associate Pathologist
Massachusetts General Hospital
Associate Professor of Pathology Harvard Medical School
Boston, Massachusetts

Kirsten Roblee, BSN, RN, OCN
Registered Nurse
The James Cancer Hospital and Solove Research Institute
Columbus, Ohio

B. Douglas Smith, MD
Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Faculty Disclosures

Robert Paul Hasserjian, MD
Consultancy: Alliance Oncology Group
Consultancy: Amgen Corp.
Consultancy: Celgene, Inc
Consultancy: Infinity Pharmaceuticals
Consultancy: Promedior, Inc
Consultancy: Sanofi Corp

Kirsten Roblee, BSN, RN, OCN
Nothing to Disclose

B. Douglas Smith, MD
Consultancy: Agios
Consultancy: Celgene
Consultancy: Jazz
Consultancy: Pfizer
Membership on a Board or Advisory Committee: AML-Combine
Membership on a Board or Advisory Committee: Hemedicus


Date of release

November 30, 2018

Date of expiration

Online access expiration and last date for learners to claim CME/MOC credit for this activity: November 29, 2019

Accreditation and Credit Designation

The American Society of Hematology (ASH) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

ASH designates this internet enduring material for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians who participate in this CME activity but are not licensed in the United States are also eligible for AMA PRA Category 1 Credit™.

ABIM Maintenance of Certification Points

Successful completion of this CME activity enables the participant to earn up to 1 Maintenance of Certification (MOC) point in the ABIM MOC program. Participants earn MOC points equivalent to the amount of CME credits claimed for the activity.

It is the CME activity provider’s responsibility to submit participant completion information to the Accreditation Council for Continuing Medical Education (ACCME) for the purpose of granting ABIM MOC credit.

ABPath Continuing Certification

In addition, participants will be eligible to earn up to 1 SAM credit for the American Board of Pathology's (ABP) Continuing Certification (formerly known as Maintenance of Certification) Program.

ONS Credit Statement:

Participants in this activity can earn a maximum of 1.00 contact hour of CNE credit. Participants must attend eligible sessions in their entirety and submit a completed evaluation within the specified time frame to receive CNE credit.

The Oncology Nursing Society is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

ONS is approved as a provider of continuing education by the California Board of Registered Nursing, Provider #2850.

The planners have no relevant information to disclose.

Claiming Credit

The estimated time to complete this educational activity is 1 hour. To claim CME/MOC credit, learners must complete both simulation scenarios, followed by the post-test of medical knowledge and an activity evaluation. The evaluation module is accessed through ASH Academy.

On November 29, 2019, online access expires. This is also the last date for users to claim credit for this activity.

For questions about credit, please contact the ASH Education Department at cme@hematology.org or call toll-free 866-828-1231 (within the United States only).